Minoryx Therapeutics’ Post

🗞 In case you missed it... Yesterday, Minoryx Therapeutics shared positive results from a compassionate use study of #leriglitazone* for the treatment of progressive #cALD - a rare, fatal neurodegenerative disorder affecting the brain. 📰 Read more about it with the official release, linked via the post below. 🔬 Read the full study here: https://bit.ly/3KGp7ow 📽 Watch the video summary of the study, here: https://bit.ly/3XeStlh *Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases.

New data published in Brain showing that #leriglitazone halts disease progression in adult patients with progressive #cALD, a fatal neurodegenerative disorder characterized by growing, demyelinating brain lesions. 🔬 Read the published paper here: https://bit.ly/3KGp7ow 📽 Watch the video summary of the study, here: https://bit.ly/3XeStlh

https://lnkd.in/eNydK3GP This skin test is a breakthrough in the early diagnosis of Parkinson's Disease and other neurological diseases. This article is well worth reading. #Worthreading

In this new article, Jay Lombard, Dr. Kiran Dintyala AKA Dr. Calm, and Niranjan Kumar, PDF, Ph.D. MTM(Management, UPENN) discuss the link between periodontal disease and systemic disorders, focusing most on the association between proteases and neurological dysfunction. Therapeutic measures can target these pathological pathways, they write: https://lnkd.in/e9RywDmN #drugtargeting #drugdiscovery #periodontitis #neurologicaldisease

This RCT supports the importance of fibrillar amyloid reduction in multiple Alzheimer disease (AD)-related processes of neuroinflammation and neurodegeneration in cerebrospinal fluid and plasma in dominantly inherited AD. https://ja.ma/3xV812R

On the eve of Rare Disease Day, we're celebrating the landmark EU approval of the first treatment for Friedreich's Ataxia in Europe. Despite falling under the "rare disease" umbrella, Friedreich's Ataxia (FA) is the most common form of ataxia worldwide, affecting an estimated 1 in every 30,000 people. It causes progressive neurological symptoms from childhood, including ataxia (muscle co-ordination difficulties), weakness, altered sensations and impaired speech, and can also cause problems with the heart. With limited treatments and an average life expectancy of around 37, the landmark approval of Skyclarys (omaveloxolone) in the EU provides new hope for FA patients. Key highlights include: • Skyclarys is thought to work by decreasing neuronal susceptibility to oxidative stress via the Nrf2 pathway, and demonstrated improved clinical scores in a 48-week study, relative to placebo • Early work performed on cell models demonstrated the beneficial effect of omaveloxolone on mitochondrial activity and oxidative stress • With the EU approval, Biogen Inc. can now work towards bringing new hope for FA patients, while opening up a new avenue for FA drug discovery Click here to read more: https://hubs.la/Q02mvRKx0 #iPSCs #FriedreichsAtaxia #DrugDiscovery #RareDiseaseDay #AtaxiaResearch

Check out this article on Alzheimer Disease!

Not good "Taken together, the only factor common to all of the patients whom we describe is treatment with the HWP subtype of c-hGH," the authors write. "Given the strong experimental evidence for [amyloid-beta] transmission from relevant archived HWP c-hGH batches, we conclude that this is the most plausible explanation for the findings observed." Investigators say the findings show that, like other prion diseases, AD has three etiologies: sporadic, inherited, and rare acquired forms, or iatrogenic AD.  "The clinical syndrome developed by these individuals can, therefore, be termed iatrogenic Alzheimer's disease, and Alzheimer's disease should now be recognized as a potentially transmissible disorder," the authors wrote. 

Hormone modulating therapy (#HMT), used in treating #breast_cancer, is linked to a 7% reduced risk of developing #Alzheimer's disease and related dementias later in life, according to a new study published in JAMA Network Open on July 16. This large-scale study discovered that while #HMT is generally associated with a protective effect against dementia, this benefit diminishes with age and differs across racial groups. To assess the risk of developing Alzheimer's disease and related dementias (#ADRD), researchers considered the risk of mortality linked to advancing age and prolonged HMT exposure. They discovered that although HMT usage generally reduced the relative risk of developing ADRD, this protective effect was strongest in patients aged 65 to 69 and lessened with increasing age. Importantly, in patients over 80, HMT users experienced a heightened risk of ADRD. #updates #ADRD #HMT #BreastCancer https://lnkd.in/diXZtEfz

Early diagnosis of Alzheimer's disease is important, but diagnosing the disease can be challenging due to overlapping symptoms and lack of definitive tests. Learn about the complexities and barriers in diagnosing this condition. Read latest blog › https://bit.ly/3XSPTBh #AlzheimersAwareness #NeurologicalResearch #NeurologicalDiseaseBiomarkerResearch